LNTH — Lantheus Holdings, Inc.
Is LNTH overbought or oversold? Here is the current MarketMoodz read.
Lantheus Holdings, Inc. (LNTH) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $99.96. The rating moved from Oversold to Neutral on October 1, 2026.
- Public ratingNeutral (as of October 3, 2026)
- Last close$99.96
- Last changeMoved from Oversold to Neutral on October 1, 2026
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
AI analysis
Lantheus Holdings, Inc. (LNTH) operates a defensive, recurring-revenue business in diagnostic imaging agents with a growing strategic emphasis on radiopharmaceuticals and theranostics. Financially, the business benefits from institutional customers and steady utilization patterns, though growth is tied to successful commercialization of pipeline assets and stable manufacturing capacity. Near-term upside is supported by recent positive corporate disclosures and sustained investor interest in late-stage specialty biotech/radiopharma themes, while downside is driven by payer reimbursement risk (including Medicare negotiation and MA dynamics), supply-chain and regulatory execution. On balance, the company presents a mix of stable cashflow characteristics and higher-return optionality from pipeline and partnership opportunities; market-wide risk aversion and policy pressures are the primary moderating factors for near-term performance.
Key factors
- Leading position in diagnostic imaging agents and radiopharmaceuticals with recurring revenue from hospital and imaging-center customers
- Growing pipeline and strategic focus on radiopharmaceutical and theranostic opportunities that can deliver higher-margin, specialty revenue
- Recent positive corporate disclosure (8-K) suggesting constructive near-term developments or operational actions
- Defensive demand characteristics for diagnostic services in risk-off market environments support more stable utilization versus elective care
- Potential for M&A, partnership or commercial expansion as late-stage specialty biotech interest and capital continues to support radiopharma valuation
Risks
- Medicare drug‑price negotiation and broader payer pricing pressure could reduce reimbursement or demand for higher-cost diagnostic agents
- Medicare Advantage benefit/price competition may compress margins for products reimbursed through MA managed care arrangements
- Manufacturing, supply-chain or distribution disruptions for radiopharmaceuticals can materially affect revenue and timing of deliveries
- Regulatory setbacks or slower-than-expected adoption of new agents/indications could delay growth catalysts
- Concentration risk across a small set of key products or customers; loss of a major contract could meaningfully impact near-term revenue
- Macro risk-off environment that cools investor appetite for healthcare/diagnostics financings and valuation multiples
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for LNTH — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.